Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
110.16
+2.40 (2.23%)
At close: May 12, 2025, 4:00 PM
111.05
+0.89 (0.81%)
After-hours: May 12, 2025, 6:32 PM EDT
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $121.46M in the quarter ending March 31, 2025, with 61.95% growth. This brings the company's revenue in the last twelve months to $432.16M, up 72.16% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$432.16M
Revenue Growth
+72.16%
P/S Ratio
12.04
Revenue / Employee
$632,734
Employees
683
Market Cap
5.42B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AXSM News
- 6 days ago - Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns - Seeking Alpha
- 7 days ago - Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Axsome Therapeutics Clocks Around 60% Topline Growth In Q1 - Benzinga
- 7 days ago - Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 11 days ago - Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month - GlobeNewsWire
- 20 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting - GlobeNewsWire